A carregar...
A Pilot Study of Bevacizumab and Interferon-α2b in Ocular Melanoma
OBJECTIVES: We hypothesized that administration of bevacizumab, a monoclonal antibody that neutralizes vascular endothelial growth factor, in combination with high-dose interferon-alpha2b (IFN-α2b), an inhibitor of basic fibroblast growth factor, would have clinical activity in patients with metasta...
Na minha lista:
| Publicado no: | Am J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4294796/ https://ncbi.nlm.nih.gov/pubmed/20458209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0b013e3181d2ed67 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|